Open in Screener

NTLA

Intellia Therapeutics Inc

Feb 05 • 04:00PM ET

11.09

-1.27 -10.28 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK XBI ARKG VTI IWM VB VBK VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-4.27	Insider Own	5.12%	Shs Outstand	115.79M	Perf Week	-20.22%
Market Cap	1.28B	Forward P/E	-	EPS next Y	-3.62	Insider Trans	1.30%	Shs Float	109.90M	Perf Month	13.98%
Enterprise Value	871.48M	PEG	-	EPS next Q	-0.95	Inst Own	91.69%	Short Float	38.72%	Perf Quarter	-9.10%
Income	-445.81M	P/S	22.33	EPS this Y	24.23%	Inst Trans	2.44%	Short Ratio	7.45	Perf Half Y	-2.46%
Sales	57.53M	P/B	1.72	EPS next Y	9.09%	ROA	-42.49%	Short Interest	42.56M	Perf YTD	23.36%
Book/sh	6.46	P/C	2.51	EPS next 5Y	33.19%	ROE	-52.11%	52W High	28.25 -60.74%	Perf Year	15.28%
Cash/sh	4.41	P/FCF	-	EPS past 3/5Y	-11.59% -20.04%	ROIC	-54.43%	52W Low	5.90 87.97%	Perf 3Y	-73.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.53% 6.07%	Gross Margin	78.27%	Volatility	8.72% 9.67%	Perf 5Y	-82.29%
Dividend TTM	-	EV/Sales	15.15	EPS Y/Y TTM	21.66%	Oper. Margin	-820.86%	ATR (14)	1.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.21	Sales Y/Y TTM	33.52%	Profit Margin	-774.94%	RSI (14)	42.49	Recom	2.28
Dividend Gr. 3/5Y	- -	Current Ratio	6.21	EPS Q/Q	31.56%	SMA20	-13.72%	Beta	2.14	Target Price	23.70
Payout	-	Debt/Eq	0.13	Sales Q/Q	51.27%	SMA50	4.23%	Rel Volume	1.02	Prev Close	12.36
Employees	403	LT Debt/Eq	0.09	Earnings	Nov 06 AMC	SMA200	-6.63%	Avg Volume	5.71M	Price	11.09
IPO	May 06, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.48% -0.94%	Trades		Volume	5,866,487	Change	-10.28%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line	$8
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight	$5
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$14
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$33
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39

Show Previous Ratings

Feb-04-26 07:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -5.29% -10.28%
Feb-02-26 09:37AM	Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal (Insider Monkey)
08:25AM	Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks) -6.81%
07:35AM	Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
06:33AM	Loading…
06:33AM	Intellia Therapeutics to resume dosing of gene therapy in Phase III trial (Clinical Trials Arena)
Jan-27-26 04:04PM	The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up (Investor's Business Daily) +6.31%
01:03PM	Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder (Benzinga)
08:31AM	Intellia gets FDA nod to resume gene therapy trial after safety pause (Reuters)
08:00AM	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN (GlobeNewswire)
06:59AM	FDA lifts hold on an Intellia CRISPR drug trial (BioPharma Dive)
Jan-22-26 08:47PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.33% -7.99%
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-15-26 10:56AM	JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death (Clinical Trials Arena)
Jan-14-26 09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average (Zacks)
07:30AM	Loading…
Jan-07-26 07:30AM	Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
Jan-02-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 01:33PM	Cathie Wood shells out $1.3 million on biotech stock (TheStreet)
09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 07:35AM	What Makes Intellia Therapeutics (NTLA) an Interesting Investment? (Insider Monkey)
Dec-29-25 09:50AM	2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street (Motley Fool)
Dec-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-25 01:41PM	Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory (Insider Monkey) +7.51%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks) +5.52%
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-25-25 08:39AM	Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress (Insider Monkey)
10:19AM	Loading…
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
04:45AM	Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data (Insider Monkey)
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-13-25 09:00AM	Should You Buy the Dip in Intellia Therapeutics Stock? (Barchart) -8.64%
Nov-12-25 09:45AM	Carvana initiated, AT upgraded: Wall Street's top analyst calls (The Fly) -6.78%
Nov-11-25 07:30AM	Is This Beaten-Down Cathie Wood Stock Still a Buy? (Barchart)
Nov-10-25 03:17PM	Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
01:19PM	Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged (Investor's Business Daily)
Nov-08-25 05:28PM	More Drugs to Fight High Cholesterol Are Emerging (The Wall Street Journal)
05:13PM	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (GlobeNewswire)
Nov-07-25 05:09PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.73%
04:14PM	Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies (Investor's Business Daily)
10:55AM	Intellia Therapeutics Says a Patient Died in Gene Editing Trial (Barrons.com)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
08:45AM	2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street (Motley Fool)
Nov-06-25 05:20PM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.21%
04:00PM	Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
Nov-05-25 11:35AM	VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? (Zacks) +11.23%
11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
Nov-04-25 10:41AM	Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint (Zacks) -6.66%
10:28AM	AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
Nov-02-25 09:25AM	Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% (Motley Fool)
Oct-31-25 01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-30-25 07:14PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -6.52%
06:54AM	FDA places formal hold on two Intellia CRISPR trials (BioPharma Dive)
Oct-29-25 06:05PM	Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates (Zacks) -6.02%
Oct-28-25 12:43PM	CRISPR Crisis: Intellia Stock Crashes 40% After Shock Trial Pause (GuruFocus.com) -5.61%
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
Oct-27-25 12:03PM	Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial (Barrons.com) -42.23%
08:25AM	Intellia stock tumbles after pausing gene therapy trials on safety concerns (Investing.com)
08:00AM	Intellia pauses two CRISPR drug studies after safety scare (BioPharma Dive)
07:30AM	Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) (GlobeNewswire)
Oct-21-25 12:56PM	Intellia (NTLA) Soars 13% to Fresh High (Insider Monkey)
Oct-20-25 09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks) +13.05%
09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks)
Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 09:23AM	Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? (Zacks)
04:59AM	Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy' (Insider Monkey)
Oct-08-25 12:00PM	Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know (Zacks) +19.72%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
09:55AM	Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know (Zacks)
09:40AM	Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-07-25 09:45AM	1 Stock Up by 63% This Year That Could Double, According to Wall Street (Motley Fool)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
Oct-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 10:47AM	Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought (Motley Fool) +8.63%
Sep-25-25 01:57PM	Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug (Benzinga) -6.48%
09:52AM	Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Sep-22-25 09:09AM	Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus (Zacks) +10.71%
07:30AM	Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 07:30AM	Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema (GlobeNewswire) +29.81%
Sep-11-25 03:45AM	Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% (Motley Fool)
Sep-10-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? (Zacks)
Sep-02-25 03:46PM	Cathie Wood Pours $4 Million Into This High-Growth Biotech Stock (GuruFocus.com)
09:03AM	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
10:59AM	Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here? (Barchart)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)
Aug-11-25 07:43AM	Take the Zacks Approach to Beat the Markets: Digi Power X, RF Industries & Starbucks in Focus (Zacks)
Aug-08-25 11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks) -5.85%
06:05AM	Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Pipeline Market Research 2025 \| Key Players Include Intellia Therapeutics, Renowned for NTLA-2001 in Phase III Development, Leveraging CRISPR/Cas9 (GlobeNewswire)
03:55AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEONARD JOHN M	President and CEO	Jan 05 '26	Sale	9.21	34,146	314,485	1,013,339	Jan 07 04:05 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Jan 05 '26	Sale	9.21	8,508	78,359	98,533	Jan 07 04:05 PM
BASTA JAMES	EVP, General Counsel	Jan 05 '26	Sale	9.21	10,397	95,756	101,528	Jan 07 04:05 PM
Cohen Fred E	Director	Jan 05 '26	Buy	9.35	150,000	1,402,500	207,453	Jan 07 04:05 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 05 '26	Sale	9.21	11,903	109,627	121,249	Jan 07 04:04 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 05 '26	Sale	9.21	9,515	87,633	87,118	Jan 07 04:03 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jan 05 '26	Sale	9.21	6,379	58,751	99,683	Jan 07 04:02 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 05 '26	Sale	9.21	2,989	27,529	52,277	Jan 07 04:01 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Option Exercise	6.83	49,959	341,220	1,127,074	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 12 '25	Option Exercise	6.83	8,557	58,444	1,047,485	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Sale	9.49	88,146	836,384	1,038,928	Dec 12 04:09 PM
LEONARD JOHN M	Officer	Dec 11 '25	Proposed Sale	9.33	88,146	822,402		Dec 11 04:11 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Oct 01 '25	Sale	17.38	31	539	105,184	Oct 03 05:13 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 01 '25	Sale	17.38	1,871	32,518	55,266	Oct 03 05:13 PM
CHASE WILLIAM J	Director	Aug 20 '25	Buy	10.03	100,000	1,003,000	134,693	Aug 22 04:30 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 23 '25	Sale	14.02	7,462	104,617	106,062	Jul 25 04:05 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '25	Sale	9.82	1,022	10,036	95,369	Jul 03 04:11 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 02 '25	Sale	9.95	2,503	24,905	57,137	Jul 03 04:07 PM
GOODMAN JESSE	Director	Jun 30 '25	Sale	9.56	1,547	14,789	25,906	Jul 02 05:50 PM
GOODMAN JESSE	Director	Jul 01 '25	Sale	9.23	1,547	14,279	24,359	Jul 02 05:50 PM
Bhanji Muna	Director	Apr 29 '25	Sale	8.50	265	2,252	19,203	May 01 04:24 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM

Open in Screener

IQV

IQVIA Holdings Inc

Feb 05 • 04:00PM ET

180.96

-21.58 -10.65 %

Healthcare • Diagnostics & Research • USA • NYSE

IQV IQVIA Holdings Inc daily Stock Chart

Peers: CROX MEDP LH ICON CTLT CRL INCY

| Held by: VTI VOO VO IVV SPY VTV XLV VOE RSP IWR

Index	S&P 500	P/E	23.03	EPS (ttm)	7.86	Insider Own	0.92%	Shs Outstand	169.60M	Perf Week	-23.20%
Market Cap	30.82B	Forward P/E	12.81	EPS next Y	14.13	Insider Trans	-5.84%	Shs Float	168.74M	Perf Month	-24.77%
Enterprise Value	44.75B	PEG	1.33	EPS next Q	2.86	Inst Own	99.00%	Short Float	2.47%	Perf Quarter	-14.22%
Income	1.36B	P/S	1.89	EPS this Y	7.19%	Inst Trans	-4.15%	Short Ratio	2.89	Perf Half Y	1.96%
Sales	16.31B	P/B	4.72	EPS next Y	10.61%	ROA	4.79%	Short Interest	4.17M	Perf YTD	-19.72%
Book/sh	38.34	P/C	14.39	EPS next 5Y	9.65%	ROE	21.64%	52W High	247.04 -26.75%	Perf Year	-9.54%
Cash/sh	12.57	P/FCF	15.03	EPS past 3/5Y	11.06% 40.52%	ROIC	6.60%	52W Low	134.65 34.40%	Perf 3Y	-21.12%
Dividend Est.	-	EV/EBITDA	13.05	Sales past 3/5Y	4.19% 7.51%	Gross Margin	26.27%	Volatility	7.76% 3.79%	Perf 5Y	1.78%
Dividend TTM	-	EV/Sales	2.74	EPS Y/Y TTM	4.62%	Oper. Margin	14.02%	ATR (14)	9.16	Perf 10Y	199.45%
Dividend Ex-Date	-	Quick Ratio	0.70	Sales Y/Y TTM	5.87%	Profit Margin	8.34%	RSI (14)	18.19	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	0.75	EPS Q/Q	23.71%	SMA20	-22.04%	Beta	1.41	Target Price	248.70
Payout	0.00%	Debt/Eq	2.45	Sales Q/Q	10.26%	SMA50	-20.95%	Rel Volume	3.15	Prev Close	202.54
Employees	88000	LT Debt/Eq	2.17	Earnings	Feb 05 BMO	SMA200	-5.60%	Avg Volume	1.44M	Price	180.96
IPO	May 09, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.64% 2.93%	Trades		Volume	4,424,805	Change	-10.65%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Nov-13-25	Initiated	BMO Capital Markets	Outperform	$260
Nov-03-25	Downgrade	TD Cowen	Buy → Hold	$215
Oct-29-25	Upgrade	Robert W. Baird	Neutral → Outperform	$258
Oct-09-25	Upgrade	HSBC Securities	Hold → Buy	$235
Sep-09-25	Upgrade	Jefferies	Hold → Buy	$225
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold	$160
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight	$170
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy	$285
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral	$248 → $202
Sep-06-23	Initiated	HSBC Securities	Buy	$260
Mar-17-23	Initiated	Truist	Buy	$265

Show Previous Ratings

Today 12:54AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
12:35AM	IQV Q4 Deep Dive: Market Cautions Despite Revenue Beat and AI Strategy Emphasis (StockStory)
Feb-05-26 04:00PM	IQVIA Holdings Inc (IQV) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -10.65%
12:11PM	IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y (Zacks)
11:55AM	IQVIA (IQV) Stock Trades Down, Here Is Why (StockStory)
09:07AM	Loading…
09:07AM	IQVIA backs AI strategy as analysts question impact on business (Reuters)
08:15AM	IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates (Zacks)
07:36AM	IQVIA's (NYSE:IQV) Q4 CY2025 Sales Top Estimates (StockStory)
07:20AM	IQVIA: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance (Business Wire)
Feb-04-26 11:40AM	IQV or IDXX: Which Is the Better Value Stock Right Now? (Zacks)
Feb-03-26 10:14PM	IQVIA (IQV) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory) -11.88%
11:23AM	IQVIA Set to Report Q4 Earnings: Here's What You Should Know (Zacks)
09:15AM	Unlocking Q4 Potential of IQVIA (IQV): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jan-29-26 08:00AM	IQVIA and Boehringer Ingelheim announce strategic long-term global commercial data foundation transformation collaboration (Business Wire)
11:44AM	Loading…
Jan-25-26 11:44AM	Beyond Biotech-3 Healthcare Stocks for Growth-Minded Investors (MarketBeat)
Jan-22-26 04:05PM	IQVIA Named to the Fortune Worlds Most Admired Companies List, Ranked No. 1 in Its Sector for Fifth Consecutive Year (Business Wire)
Jan-20-26 04:45PM	IQVIA to Announce Fourth-Quarter and Full-Year 2025 Results on February 5, 2026 (Business Wire)
Jan-15-26 09:36AM	3 Medical Device Companies in Focus for Monetizing Data and Analytics (Zacks)
Jan-14-26 09:50AM	Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-13-26 09:11AM	What You Need To Know Ahead of IQVIAs Earnings Release (Barchart)
Jan-12-26 11:36PM	2 Large-Cap Stocks Worth Your Attention and 1 We Turn Down (StockStory)
Jan-11-26 11:04PM	3 Reasons to Sell IQV and 1 Stock to Buy Instead (StockStory)
Jan-09-26 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
Dec-29-25 12:55PM	Here's Why You Should Retain IQV Stock in Your Portfolio Now (Zacks)
Dec-17-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-09-25 10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
09:50AM	Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-04-25 12:21PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily)
Dec-03-25 10:32PM	Is IQVIA Holdings Stock Outperforming the S&P 500? (Barchart)
08:00AM	Loading…
Dec-02-25 08:00AM	IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform (Business Wire)
Nov-28-25 11:30AM	Glaukos (GKOS) Up 20% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-27-25 11:30AM	Why Is IQVIA (IQV) Up 6.4% Since Last Earnings Report? (Zacks)
Nov-26-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Nov-11-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-06-25 10:32PM	Q3 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
12:38PM	GDOT Gears Up to Report Q3 Earnings: Here's What You Should Know (Zacks)
12:33PM	Mogo Set to Report Q3 Earnings: Here's What Investors Should Know (Zacks)
Nov-05-25 04:15PM	Dr. William G. Kaelin Jr. joins IQVIA Board of Directors (Business Wire)
09:40AM	IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Nov-04-25 12:31AM	IQVIA's Q3 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Nov-03-25 01:15PM	Why IQVIA (IQV) Shares Are Trading Lower Today (StockStory)
09:42AM	Boeing upgraded, Charter downgraded: Wall Street's top analyst calls (The Fly)
Oct-30-25 03:14PM	IQVIA Holdings Inc (IQV) Q3 2025 Earnings Call Highlights: Record Free Cash Flow and Strong ... (GuruFocus.com)
Oct-29-25 03:45PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
01:31AM	IQV Q3 Deep Dive: Clinical Research Demand and AI Initiatives Drive Steady Growth (StockStory)
Oct-28-25 08:00PM	IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
01:09PM	IQVIA Earnings & Revenues Beat Estimates in Q3, Increase Y/Y (Zacks)
08:15AM	IQVIA Holdings (IQV) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:28AM	IQVIA (NYSE:IQV) Beats Q3 Sales Expectations (StockStory)
07:14AM	IQVIA: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Third-Quarter 2025 Results (Business Wire)
Oct-26-25 11:08PM	IQVIA (IQV) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-23-25 10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-22-25 10:00AM	TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 04:15PM	IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025 (Business Wire)
10:00AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-20-25 01:35PM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
Oct-15-25 04:25AM	What to Expect From IQVIA Holdings Next Quarterly Earnings Report (Barchart)
Oct-10-25 12:00AM	3 Reasons to Sell IQV and 1 Stock to Buy Instead (StockStory)
Oct-09-25 09:37AM	Oracle initiated, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Oct-01-25 06:48PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research) +7.29%
04:01PM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
10:10AM	Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma? (Zacks)
Sep-30-25 04:15PM	IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 (Business Wire) +5.10%
Sep-29-25 09:43AM	What Makes IQVIA (IQV) an Attractive Investment? (Insider Monkey)
Sep-19-25 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
08:58AM	What Makes IQVIA (IQV) a Good Investment? (Insider Monkey)
Sep-16-25 08:00AM	IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships (Business Wire)
Sep-11-25 02:16PM	Why IQVIA (IQV) Stock Is Up Today (StockStory)
06:09AM	How Is IQVIA Holdings' Stock Performance Compared to Other Health Tech Stocks? (Barchart)
Sep-10-25 08:00AM	IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management (Business Wire)
04:54AM	IQVIA Holdings Inc. (IQV) and Flagship Pioneering Partner to Accelerate Growth of Breakthrough Life Sciences Companies (Insider Monkey)
Sep-09-25 12:11PM	Jefferies backs IQVIA and Charles River, cuts ICON on customer losses (Investing.com)
Sep-03-25 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
Sep-02-25 09:00AM	IQVIA Announces CFO Transition in Early 2026 (Business Wire)
Aug-29-25 11:30AM	Why Is DexCom (DXCM) Down 7% Since Last Earnings Report? (Zacks)
Aug-28-25 08:00AM	IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies (PR Newswire)
Aug-27-25 09:55AM	IQVIA Holdings Inc. (IQV): A Bull Case Theory (Insider Monkey)
Aug-22-25 08:29AM	What Are Wall Street Analysts' Target Price for IQVIA Holdings Stock? (Barchart)
Aug-21-25 11:30AM	IQVIA (IQV) Down 1.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-18-25 11:31PM	Q2 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
09:00AM	IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes (Business Wire)
Aug-14-25 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
02:42AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Aug-13-25 10:57AM	UMAC Gears Up to Report Q2 Earnings: What's in the Offing? (Zacks)
Aug-11-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
05:19AM	Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion (PR Newswire)
Aug-06-25 06:42PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
12:24PM	Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss (Zacks)
Aug-05-25 12:23PM	Gartner Earnings Surpass Estimates in Q2, Revenues Increase Y/Y (Zacks)
Jul-30-25 10:42AM	Verisk Earnings & Revenues Surpass Estimates in Q2, Increase Y/Y (Zacks)
Jul-29-25 12:44PM	WM Earnings & Revenues Beat Estimates in Q2, Increase Y/Y (Zacks)
12:41PM	Fiserv Q2 Earnings Beat Estimates on Strong Margins, Revenues Miss (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
01:34AM	5 Revealing Analyst Questions From IQVIA's Q2 Earnings Call (StockStory)
Jul-28-25 10:45AM	IQVIA (IQV) Reliance on International Sales: What Investors Need to Know (Zacks)
Jul-24-25 06:37PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
11:17AM	Veeva's Vault Vision: Can It Thrive After Parting With Salesforce? (Zacks)
Jul-23-25 02:23PM	IQVIA Holdings (IQV) Snaps 2-Day Losses on Higher-than-Expected Earnings (Insider Monkey)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOUSBIB ARI	See Remarks	Dec 18 '25	Option Exercise	59.90	50,000	2,995,000	857,163	Dec 19 05:00 PM
BOUSBIB ARI	See Remarks	Dec 18 '25	Sale	222.43	36,564	8,132,931	820,599	Dec 19 05:00 PM
ARI BOUSBIB	Officer	Dec 18 '25	Proposed Sale	222.43	36,564	8,132,876		Dec 18 05:41 PM
Sherbet Eric	See Remarks	Oct 29 '25	Option Exercise	131.82	10,000	1,318,200	31,108	Oct 31 05:01 PM
Sherbet Eric	See Remarks	Oct 29 '25	Sale	219.70	4,000	878,800	27,108	Oct 31 05:01 PM
BOUSBIB ARI	See Remarks	Oct 29 '25	Option Exercise	59.90	77,592	4,647,761	884,755	Oct 31 05:00 PM
BOUSBIB ARI	See Remarks	Oct 29 '25	Sale	220.33	56,557	12,461,119	828,198	Oct 31 05:00 PM
ARI BOUSBIB	Officer	Oct 29 '25	Proposed Sale	220.33	56,557	12,460,983		Oct 29 04:18 PM
ERIC SHERBET	Officer	Oct 29 '25	Proposed Sale	219.70	4,000	878,820		Oct 29 04:10 PM
Cherofsky Keriann	See Remarks	Jul 23 '25	Sale	191.53	549	105,150	2,910	Jul 25 05:01 PM
Sherbet Eric	See Remarks	Jul 23 '25	Option Exercise	97.20	11,870	1,153,764	32,978	Jul 25 05:00 PM
Sherbet Eric	See Remarks	Jul 23 '25	Sale	190.05	5,800	1,102,290	27,178	Jul 25 05:00 PM
ERIC SHERBET	Officer	Jul 23 '25	Proposed Sale	190.05	5,800	1,102,262		Jul 23 05:53 PM
KERIANN CHEROFSKY	Officer	Jul 23 '25	Proposed Sale	191.53	549	105,150		Jul 23 04:01 PM
BOUSBIB ARI	See Remarks	Feb 10 '25	Option Exercise	65.16	40,000	2,606,400	837,083	Feb 12 05:11 PM

NTLA

Intellia Therapeutics Inc

IQV

IQVIA Holdings Inc

Upgrade your FINVIZ experience